Free tool
FAERS Monitor: Allegra Hives
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020872 or its brand name (Allegra Hives, Fexofenadine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
21,085
Serious
6,968
33% of reports
Hospitalization
2,858
Death reported
575
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective3,718
- headache953
- fatigue928
- pruritus921
- nausea816
- no adverse event780
- diarrhoea738
- dizziness707
- extra dose administered701
- rash678
- dyspnoea665
- somnolence611
- cough608
- insomnia548
- pain546
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 148 |
| 2005 | 140 |
| 2006 | 29 |
| 2007 | 31 |
| 2008 | 37 |
| 2009 | 48 |
| 2010 | 20 |
| 2011 | 37 |
| 2012 | 118 |
| 2013 | 159 |
| 2014 | 170 |
| 2015 | 358 |
| 2016 | 1,977 |
| 2017 | 2,191 |
| 2018 | 2,693 |
| 2019 | 1,215 |
| 2020 | 1,203 |
| 2021 | 1,220 |
| 2022 | 1,457 |
| 2023 | 2,021 |
| 2024 | 1,938 |
| 2025 | 2,049 |
| 2026 | 1,826 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,033,074 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| extra dose administeredSignal | 701 | 17.5 | 16.3 | 10,755 |
| no adverse eventSignal | 780 | 4.3 | 4.0 | 1,987 |
| somnolenceSignal | 611 | 3.0 | 2.8 | 836 |
| drug ineffectiveSignal | 3,718 | 2.8 | 2.7 | 4,642 |
| pruritusSignal | 921 | 2.4 | 2.2 | 758 |
| coughSignal | 608 | 2.2 | 2.0 | 384 |
| insomniaSignal | 548 | 2.1 | 1.9 | 299 |
| rash | 678 | 1.6 | 1.4 | 135 |
| headache | 953 | 1.5 | 1.4 | 172 |
| dizziness | 707 | 1.4 | 1.3 | 87 |
| fatigue | 928 | 1.2 | 1.1 | 29 |
| dyspnoea | 665 | 1.2 | 1.1 | 17 |
| diarrhoea | 738 | 1.1 | 1.1 | 13 |
| nausea | 816 | 1.0 | 1.0 | 1 |
| pain | 546 | 0.9 | 0.8 | 8 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.